Please ensure Javascript is enabled for purposes of website accessibility

NVIDIA Is Building an AI Supercomputer for Healthcare Research in England

By Anders Bylund – Updated Oct 5, 2020 at 1:50PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This powerful system is just the start of the company's plans for a healthcare-focused AI hub on the Cambridge campus.

Semiconductor designer NVIDIA (NVDA -0.83%) today announced that it is building the United Kingdom's most powerful supercomputer ever. Dubbed Cambridge-1, the system will give healthcare researchers access to impressive artificial intelligence (AI) tools.

The $52 million Cambridge-1 will be installed at the university it's named after, and is scheduled to come online by the end of 2020. It is designed around NVIDIA's DGX SuperPOD platform, which in turn employs NVIDIA's Tensor Core processors. The modular nature of the DGX SuperPOD platform allows NVIDIA to install and power up the new system in a matter of weeks, where traditional supercomputers often are years in the making.

The Tensor Core chips are specifically designed to accelerate AI computing. As a result, Cambridge-1 will deliver a general LINPACK performance score of 8 petaflops (quadrillions of floating-point operations per second) but as much as 400 petaflops in AI-specific workloads.

8 petaflops are nothing to sneeze at, making Cambridge-1 the 29th most powerful general computing system on the TOP 500 list of ultra-powerful supercomputers. NVIDIA chips can be found in 15 of the 28 supercomputers ranked higher than Cambridge-1.

A digital imaghe of a heart hovers in the air between a doctor's hand and a robot hand.

Image source: Getty Images.

This installation is the start of NVIDIA's intention to build an AI center of excellence on the Cambridge campus, providing a pan-European hub for AI-based research and collaboration among healthcare scientists and start-ups in the region.

Early users of the Cambridge-1 system will include pharmaceutical giants AstraZeneca (AZN -0.17%) and GlaxoSmithKline (GSK 1.48%). The companies hope to find solutions to difficult medical challenges with the help of powerful AI algorithms.

"Accelerating drug discovery has never been so important, and it is investments like this that can make a real difference in our fight against countless diseases," said Matt Hancock, the U.K. secretary of state for health and social care.

Anders Bylund has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends NVIDIA. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Nvidia Stock Quote
Nvidia
NVDA
$156.96 (-0.83%) $-1.31
GSK plc Stock Quote
GSK plc
GSK
$34.26 (1.48%) $0.50
AstraZeneca PLC Stock Quote
AstraZeneca PLC
AZN
$66.09 (-0.17%) $0.12

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
351%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.